Literature DB >> 24862344

The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale.

Albert F G Leentjens1, Kathy Dujardin, Gregory M Pontone, Sergio E Starkstein, Daniel Weintraub, Pablo Martinez-Martin.   

Abstract

Existing anxiety rating scales have limited construct validity in patients with Parkinson's disease (PD). This study was undertaken to develop and validate a new anxiety rating scale, the Parkinson Anxiety Scale (PAS), that would overcome the limitations of existing scales. The general structure of the PAS was based on the outcome of a Delphi procedure. Item selection was based on a canonical correlation analysis and a Rasch analysis of items of the Hamilton Anxiety Rating Scale (HARS) and the Beck Anxiety Inventory (BAI) from a previously published study. Validation was done in a cross-sectional international multicenter study involving 362 patients with idiopathic PD. Patients underwent a single screening session in which the PAS was administered, along with the Hamilton Depression Rating Scale, the HARS, and the BAI. The Mini International Neuropsychiatric Interview was administered to establish Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnoses of anxiety and depressive disorders. The PAS is a 12-item observer or patient-rated scale with three subscales, for persistent, episodic anxiety and avoidance behavior. Properties for acceptability and reliability met predetermined criteria. The convergent and known groups validity was good. The scale has a satisfactory factorial structure. The area under the receiver operating characteristics curve and Youden index of the PAS are higher than that of existing anxiety rating scales. The PAS is a reliable and valid anxiety measure for use in PD patients. It is easy and brief to administer, and has better clinimetric properties than existing anxiety rating scales. The sensitivity to change of the PAS remains to be assessed.
© 2014 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; anxiety; depression; rating scale; ‘non-motor’ symptoms

Mesh:

Year:  2014        PMID: 24862344     DOI: 10.1002/mds.25919

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  55 in total

1.  Neuropsychiatric characteristics of GBA-associated Parkinson disease.

Authors:  Matthew Swan; Nancy Doan; Robert A Ortega; Matthew Barrett; William Nichols; Laurie Ozelius; Jeannie Soto-Valencia; Sarah Boschung; Andres Deik; Harini Sarva; Jose Cabassa; Brooke Johannes; Deborah Raymond; Karen Marder; Nir Giladi; Joan Miravite; William Severt; Rivka Sachdev; Vicki Shanker; Susan Bressman; Rachel Saunders-Pullman
Journal:  J Neurol Sci       Date:  2016-08-30       Impact factor: 3.181

Review 2.  Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease.

Authors:  Christoph Mueller; Anto P Rajkumar; Yi Min Wan; Latha Velayudhan; Dominic Ffytche; Kallol Ray Chaudhuri; Dag Aarsland
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749

3.  The relation of anxiety and cognition in Parkinson's disease.

Authors:  Gretchen O Reynolds; Kristine K Hanna; Sandy Neargarder; Alice Cronin-Golomb
Journal:  Neuropsychology       Date:  2017-04-20       Impact factor: 3.295

4.  Presleep Cognitive Arousal and Insomnia Comorbid to Parkinson Disease: Evidence for a Serial Mediation Model of Sleep-Related Safety Behaviors and Dysfunctional Beliefs About Sleep.

Authors:  Cindy Lebrun; Marie-Christine Gély-Nargeot; Khaalid Hassan Maudarbocus; Alexia Rossignol; Christian Geny; Sophie Bayard
Journal:  J Clin Sleep Med       Date:  2019-09-15       Impact factor: 4.062

5.  A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.

Authors:  Ruth B Schneider; Peggy Auinger; Christopher G Tarolli; Julia Iourinets; María Cristina Gil-Díaz; Irene H Richard
Journal:  Parkinsonism Relat Disord       Date:  2020-10-13       Impact factor: 4.891

6.  Cognitive phenotypes in parkinson's disease differ in terms of brain-network organization and connectivity.

Authors:  Renaud Lopes; Christine Delmaire; Luc Defebvre; Anja J Moonen; Annelien A Duits; Paul Hofman; Albert F G Leentjens; Kathy Dujardin
Journal:  Hum Brain Mapp       Date:  2016-11-17       Impact factor: 5.038

Review 7.  Neuropsychiatric aspects of Parkinson's disease.

Authors:  Anna Nagy; Anette Schrag
Journal:  J Neural Transm (Vienna)       Date:  2019-05-29       Impact factor: 3.575

Review 8.  Lewy Body Degenerations as Neuropsychiatric Disorders.

Authors:  Jared T Hinkle; Gregory M Pontone
Journal:  Psychiatr Clin North Am       Date:  2020-04-08

Review 9.  Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease: A Meta-Analysis of Mood Effects.

Authors:  Tomas Cartmill; David Skvarc; Richard Bittar; Jane McGillivray; Michael Berk; Linda K Byrne
Journal:  Neuropsychol Rev       Date:  2021-02-19       Impact factor: 7.444

10.  The impact of motor symptoms on self-reported anxiety in Parkinson's disease.

Authors:  Robert D Salazar; Asher M Le; Sandy Neargarder; Alice Cronin-Golomb
Journal:  Parkinsonism Relat Disord       Date:  2017-01-24       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.